A Phase 4 interventional study of salbutamol and Placebo in Asthma, sponsored by University of Saskatchewan. Completed at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2012-07-20.
Sponsored by University of Saskatchewan · Phase 4, Interventional, and Basic science
Overuse of inhaled bronchodilator beta agonist medication results in a loss of effectiveness (i.e. tolerance). This has been shown for the short acting beta agonist salbutamol and the long acting beta agonist salmeterol. Tolerance to salmeterol is present within 24 hours. The onset of tolerance to salbutamol is not known.
University of Saskatchewan is the lead sponsor of 237 studies on the registry; 33 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: salbutamol
200mcg twice daily for a total of 7 doses
Drug: Placebo
200mcg twice daily for a total of 7 doses
200mcg twice a day for a total of 7 doses (3.5 days).
Airway responsiveness as a measure of salbutamol bronchoprotection
Regular use of salbutamol results in loss of bronchoprotection. The primary outcome is to determine the onset of this tolerance.
Time frame: ten minutes post 200mcg salbutamol on day 1
Airway responsiveness as a measure of salbutamol bronchoprotection
Regular use of salbutamol results in loss of bronchoprotection. The primary outcome is to determine the onset of this tolerance.
Time frame: ten minutes post 200mcg salbutamol on day 3
Airway responsiveness as a measure of bronchoprotection. The primary outcome is to determine the onset of this tolerance.
Regular use of salbutamol results in loss of bronchoprotection. The primary outcome is to determine the onset of this tolerance.
Time frame: ten minutes post 200mcg salbutamol on day 5
Airway responsiveness as a measure of salbutamol bronchoprotection
Regular use of salbutamol results in loss of bronchoprotection. The primary outcome is to determine the onset of this tolerance.
Time frame: ten minutes post 200mcg salbutamol on day 7
This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Saskatchewan